U
Global Cord Blood Corporation
CORBF
$1.02
-$0.13-11.30%
D
Sell
3/1/2023Downgrade
Global Cord Blood Corporation (CORBF) was downgraded to D+ from C- on 03/01/2023.
Global Cord Blood Corporation (CORBF) was downgraded to D+ from C- on 03/01/2023.
C
Hold
2/14/2023Upgraded
Global Cord Blood Corporation (CO) was upgraded to C- from D+ on 2/14/2023 due to an increase in the volatility index and total return index.
Global Cord Blood Corporation (CO) was upgraded to C- from D+ on 2/14/2023 due to an increase in the volatility index and total return index.
D
Sell
11/23/2022Upgraded
Global Cord Blood Corporation (CO) was upgraded to D+ from D on 11/23/2022 due to an increase in the total return index and volatility index.
Global Cord Blood Corporation (CO) was upgraded to D+ from D on 11/23/2022 due to an increase in the total return index and volatility index.
D
Sell
11/8/2022Downgrade
Global Cord Blood Corporation (CO) was downgraded to D from D+ on 11/8/2022 due to a decline in the volatility index.
Global Cord Blood Corporation (CO) was downgraded to D from D+ on 11/8/2022 due to a decline in the volatility index.
D
Sell
10/20/2022Upgraded
Global Cord Blood Corporation (CO) was upgraded to D+ from D on 10/20/2022 due to an increase in the volatility index and total return index.
Global Cord Blood Corporation (CO) was upgraded to D+ from D on 10/20/2022 due to an increase in the volatility index and total return index.
D
Sell
10/3/2022Downgrade
Global Cord Blood Corporation (CO) was downgraded to D from D+ on 10/3/2022 due to a decline in the valuation index, volatility index and total return index.
Global Cord Blood Corporation (CO) was downgraded to D from D+ on 10/3/2022 due to a decline in the valuation index, volatility index and total return index.
D
Sell
9/8/2022Upgraded
Global Cord Blood Corporation (CO) was upgraded to D+ from D on 9/8/2022 due to an increase in the valuation index and volatility index.
Global Cord Blood Corporation (CO) was upgraded to D+ from D on 9/8/2022 due to an increase in the valuation index and volatility index.
D
Sell
8/22/2022Downgrade
Global Cord Blood Corporation (CO) was downgraded to D from D+ on 8/22/2022 due to a significant decline in the growth index, efficiency index and valuation index. Earnings per share declined from $0.1592 to $0.1351, net income declined 15.12% from $19.43M to $16.5M, and EBIT declined 9.71% from $24.8M to $22.39M.
Global Cord Blood Corporation (CO) was downgraded to D from D+ on 8/22/2022 due to a significant decline in the growth index, efficiency index and valuation index. Earnings per share declined from $0.1592 to $0.1351, net income declined 15.12% from $19.43M to $16.5M, and EBIT declined 9.71% from $24.8M to $22.39M.
D
Sell
7/21/2022Downgrade
Global Cord Blood Corporation (CO) was downgraded to D+ from C- on 7/21/2022 due to a decline in the total return index and volatility index.
Global Cord Blood Corporation (CO) was downgraded to D+ from C- on 7/21/2022 due to a decline in the total return index and volatility index.
C
Hold
3/21/2022Downgrade
Global Cord Blood Corporation (CO) was downgraded to C- from C on 3/21/2022 due to a decline in the total return index and volatility index.
Global Cord Blood Corporation (CO) was downgraded to C- from C on 3/21/2022 due to a decline in the total return index and volatility index.
C
Hold
3/2/2022Upgraded
Global Cord Blood Corporation (CO) was upgraded to C from C- on 3/2/2022 due to a substantial increase in the growth index, valuation index and efficiency index.
Global Cord Blood Corporation (CO) was upgraded to C from C- on 3/2/2022 due to a substantial increase in the growth index, valuation index and efficiency index.
C
Hold
12/6/2021Downgrade
Global Cord Blood Corporation (CO) was downgraded to C- from C on 12/6/2021 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.1618 to $0.1592, and net income declined 1.4% from $19.71M to $19.43M.
Global Cord Blood Corporation (CO) was downgraded to C- from C on 12/6/2021 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.1618 to $0.1592, and net income declined 1.4% from $19.71M to $19.43M.
C
Hold
9/17/2021Downgrade
Global Cord Blood Corporation (CO) was downgraded to C from C+ on 9/17/2021 due to a decline in the volatility index, total return index and valuation index.
Global Cord Blood Corporation (CO) was downgraded to C from C+ on 9/17/2021 due to a decline in the volatility index, total return index and valuation index.
C
Hold
9/2/2021Upgraded
Global Cord Blood Corporation (CO) was upgraded to C+ from C on 9/2/2021 due to an increase in the valuation index, growth index and total return index. EBIT increased 13.7% from $20.12M to $22.88M, total revenue increased 12.98% from $41.3M to $46.66M, and earnings per share increased from $0.1562 to $0.1618.
Global Cord Blood Corporation (CO) was upgraded to C+ from C on 9/2/2021 due to an increase in the valuation index, growth index and total return index. EBIT increased 13.7% from $20.12M to $22.88M, total revenue increased 12.98% from $41.3M to $46.66M, and earnings per share increased from $0.1562 to $0.1618.
C
Hold
7/29/2021Downgrade
Global Cord Blood Corporation (CO) was downgraded to C from C+ on 7/29/2021 due to a decline in the total return index and volatility index.
Global Cord Blood Corporation (CO) was downgraded to C from C+ on 7/29/2021 due to a decline in the total return index and volatility index.
C
Hold
5/27/2021Upgraded
Global Cord Blood Corporation (CO) was upgraded to C+ from C on 5/27/2021 due to a noticeable increase in the total return index, volatility index and growth index.
Global Cord Blood Corporation (CO) was upgraded to C+ from C on 5/27/2021 due to a noticeable increase in the total return index, volatility index and growth index.
C
Hold
4/5/2021Upgraded
Global Cord Blood Corporation (CO) was upgraded to C from C- on 4/5/2021 due to a substantial increase in the growth index, valuation index and volatility index.
Global Cord Blood Corporation (CO) was upgraded to C from C- on 4/5/2021 due to a substantial increase in the growth index, valuation index and volatility index.
C
Hold
2/8/2021Upgraded
Global Cord Blood Corporation (CO) was upgraded to C- from D+ on 2/8/2021 due to an increase in the total return index and volatility index.
Global Cord Blood Corporation (CO) was upgraded to C- from D+ on 2/8/2021 due to an increase in the total return index and volatility index.
D
Sell
9/10/2020Upgraded
Global Cord Blood Corporation (CO) was upgraded to D+ from D on 9/10/2020 due to an increase in the total return index and valuation index.
Global Cord Blood Corporation (CO) was upgraded to D+ from D on 9/10/2020 due to an increase in the total return index and valuation index.
D
Sell
8/26/2020Downgrade
Global Cord Blood Corporation (CO) was downgraded to D from D+ on 8/26/2020 due to a decline in the volatility index and valuation index.
Global Cord Blood Corporation (CO) was downgraded to D from D+ on 8/26/2020 due to a decline in the volatility index and valuation index.
D
Sell
8/7/2020Upgraded
Global Cord Blood Corporation (CO) was upgraded to D+ from D on 8/7/2020 due to an increase in the volatility index.
Global Cord Blood Corporation (CO) was upgraded to D+ from D on 8/7/2020 due to an increase in the volatility index.
D
Sell
5/26/2020Downgrade
Global Cord Blood Corporation (CO) was downgraded to D from D+ on 5/26/2020 due to a decline in the total return index, volatility index and solvency index.
Global Cord Blood Corporation (CO) was downgraded to D from D+ on 5/26/2020 due to a decline in the total return index, volatility index and solvency index.
D
Sell
12/4/2019Downgrade
Global Cord Blood Corporation (CO) was downgraded to D+ from C- on 12/4/2019 due to a decline in the volatility index, total return index and valuation index.
Global Cord Blood Corporation (CO) was downgraded to D+ from C- on 12/4/2019 due to a decline in the volatility index, total return index and valuation index.
C
Hold
9/18/2019Downgrade
Global Cord Blood Corporation (CO) was downgraded to C- from C on 9/18/2019 due to a decline in the volatility index and total return index.
Global Cord Blood Corporation (CO) was downgraded to C- from C on 9/18/2019 due to a decline in the volatility index and total return index.
C
Hold
8/30/2019Upgraded
Global Cord Blood Corporation (CO) was upgraded to C from C- on 8/30/2019 due to a significant increase in the growth index, valuation index and efficiency index. EBIT increased 25.08% from $13.17M to $16.48M, earnings per share increased from $0.1097 to $0.1305, and net income increased 17.6% from $13.51M to $15.88M.
Global Cord Blood Corporation (CO) was upgraded to C from C- on 8/30/2019 due to a significant increase in the growth index, valuation index and efficiency index. EBIT increased 25.08% from $13.17M to $16.48M, earnings per share increased from $0.1097 to $0.1305, and net income increased 17.6% from $13.51M to $15.88M.
C
Hold
8/28/2019Downgrade
Global Cord Blood Corporation (CO) was downgraded to C- from C on 8/28/2019 due to a major decline in the growth index, total return index and efficiency index. EBIT declined 14.42% from $15.39M to $13.17M.
Global Cord Blood Corporation (CO) was downgraded to C- from C on 8/28/2019 due to a major decline in the growth index, total return index and efficiency index. EBIT declined 14.42% from $15.39M to $13.17M.
C
Hold
3/4/2019Upgraded
Global Cord Blood Corporation (CO) was upgraded to C from D+ on 3/4/2019 due to a significant increase in the growth index, valuation index and efficiency index.
Global Cord Blood Corporation (CO) was upgraded to C from D+ on 3/4/2019 due to a significant increase in the growth index, valuation index and efficiency index.
D
Sell
12/10/2018Downgrade
Global Cord Blood Corporation (CO) was downgraded to D+ from C- on 12/10/2018 due to a decline in the volatility index.
Global Cord Blood Corporation (CO) was downgraded to D+ from C- on 12/10/2018 due to a decline in the volatility index.
C
Hold
12/7/2018Downgrade
Global Cord Blood Corporation (CO) was downgraded to C- from C on 12/7/2018 due to a substantial decline in the growth index, volatility index and total return index. Total revenue declined 0.96% from $36.65M to $36.3M.
Global Cord Blood Corporation (CO) was downgraded to C- from C on 12/7/2018 due to a substantial decline in the growth index, volatility index and total return index. Total revenue declined 0.96% from $36.65M to $36.3M.
C
Hold
3/6/2018Upgraded
China Cord Blood Corporation (CO) was upgraded to C from C- on 3/6/2018 due to a major increase in the growth index, valuation index and efficiency index.
China Cord Blood Corporation (CO) was upgraded to C from C- on 3/6/2018 due to a major increase in the growth index, valuation index and efficiency index.
C
Hold
2/9/2018Downgrade
China Cord Blood Corporation (CO) was downgraded to C- from C on 2/9/2018 due to a significant decline in the total return index and volatility index.
China Cord Blood Corporation (CO) was downgraded to C- from C on 2/9/2018 due to a significant decline in the total return index and volatility index.
C
Hold
8/25/2017Upgraded
China Cord Blood Corporation (CO) was upgraded to C from C- on 8/25/2017 due to an increase in the growth index, efficiency index and total return index.
China Cord Blood Corporation (CO) was upgraded to C from C- on 8/25/2017 due to an increase in the growth index, efficiency index and total return index.
C
Hold
7/28/2017Downgrade
China Cord Blood Corporation (CO) was downgraded to C- from C on 7/28/2017 due to a major decline in the growth index, valuation index and efficiency index. EBIT declined 0.36% from $8.21M to $8.18M.
China Cord Blood Corporation (CO) was downgraded to C- from C on 7/28/2017 due to a major decline in the growth index, valuation index and efficiency index. EBIT declined 0.36% from $8.21M to $8.18M.
C
Hold
7/19/2017Downgrade
China Cord Blood Corporation (CO) was downgraded to C from C+ on 7/19/2017 due to a decline in the valuation index.
China Cord Blood Corporation (CO) was downgraded to C from C+ on 7/19/2017 due to a decline in the valuation index.
C
Hold
6/14/2017Upgraded
China Cord Blood Corporation (CO) was upgraded to C+ from C on 6/14/2017 due to a significant increase in the total return index and volatility index.
China Cord Blood Corporation (CO) was upgraded to C+ from C on 6/14/2017 due to a significant increase in the total return index and volatility index.
C
Hold
2/27/2017Upgraded
China Cord Blood Corporation (CO) was upgraded to C from C- on 2/27/2017 due to a major increase in the valuation index, growth index and volatility index.
China Cord Blood Corporation (CO) was upgraded to C from C- on 2/27/2017 due to a major increase in the valuation index, growth index and volatility index.
C
Hold
12/27/2016Upgraded
China Cord Blood Corporation (CO) was upgraded to C- from D+ on 12/27/2016 due to an increase in the volatility index and total return index.
China Cord Blood Corporation (CO) was upgraded to C- from D+ on 12/27/2016 due to an increase in the volatility index and total return index.
D
Sell
12/12/2016Downgrade
China Cord Blood Corporation (CO) was downgraded to D+ from C- on 12/12/2016 due to a major decline in the volatility index, solvency index and efficiency index. The quick ratio declined from 6.71 to 3.43, and total capital declined 1.75% from $415.17M to $407.89M.
China Cord Blood Corporation (CO) was downgraded to D+ from C- on 12/12/2016 due to a major decline in the volatility index, solvency index and efficiency index. The quick ratio declined from 6.71 to 3.43, and total capital declined 1.75% from $415.17M to $407.89M.
C
Hold
8/3/2016Downgrade
China Cord Blood Corporation (CO) was downgraded to C- from C on 8/3/2016 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 57.57% from $2.97M to $1.26M, earnings per share declined from $0.0397 to $0.0264, and EBIT declined 27.16% from $8.33M to $6.06M.
China Cord Blood Corporation (CO) was downgraded to C- from C on 8/3/2016 due to a significant decline in the growth index, valuation index and efficiency index. Net income declined 57.57% from $2.97M to $1.26M, earnings per share declined from $0.0397 to $0.0264, and EBIT declined 27.16% from $8.33M to $6.06M.
C
Hold
7/19/2016Downgrade
China Cord Blood Corporation (CO) was downgraded to C from C+ on 7/19/2016 due to a decline in the total return index and volatility index.
China Cord Blood Corporation (CO) was downgraded to C from C+ on 7/19/2016 due to a decline in the total return index and volatility index.
C
Hold
5/3/2016Upgraded
China Cord Blood Corporation (CO) was upgraded to C+ from C on 5/3/2016 due to an increase in the volatility index and total return index.
China Cord Blood Corporation (CO) was upgraded to C+ from C on 5/3/2016 due to an increase in the volatility index and total return index.
C
Hold
4/1/2016Downgrade
China Cord Blood Corporation (CO) was downgraded to C from C+ on 4/1/2016 due to a decline in the valuation index and volatility index.
China Cord Blood Corporation (CO) was downgraded to C from C+ on 4/1/2016 due to a decline in the valuation index and volatility index.
C
Hold
3/18/2016Downgrade
China Cord Blood Corporation (CO) was downgraded to C+ from B- on 3/18/2016 due to a substantial decline in the volatility index, total return index and valuation index.
China Cord Blood Corporation (CO) was downgraded to C+ from B- on 3/18/2016 due to a substantial decline in the volatility index, total return index and valuation index.
B
Buy
3/3/2016Upgraded
China Cord Blood Corporation (CO) was upgraded to B- from C on 3/3/2016 due to a large increase in the growth index, valuation index and efficiency index.
China Cord Blood Corporation (CO) was upgraded to B- from C on 3/3/2016 due to a large increase in the growth index, valuation index and efficiency index.
C
Hold
12/11/2015Downgrade
China Cord Blood Corporation (CO) was downgraded to C from B- on 12/11/2015 due to a substantial decline in the total return index, valuation index and efficiency index.
China Cord Blood Corporation (CO) was downgraded to C from B- on 12/11/2015 due to a substantial decline in the total return index, valuation index and efficiency index.
B
Buy
8/28/2015Upgraded
China Cord Blood Corporation (CO) was upgraded to B- from C+ on 8/28/2015 due to an increase in the valuation index, total return index and growth index.
China Cord Blood Corporation (CO) was upgraded to B- from C+ on 8/28/2015 due to an increase in the valuation index, total return index and growth index.
C
Hold
8/13/2015Downgrade
China Cord Blood Corporation (CO) was downgraded to C+ from B- on 8/13/2015 due to a decline in the valuation index.
China Cord Blood Corporation (CO) was downgraded to C+ from B- on 8/13/2015 due to a decline in the valuation index.
B
Buy
8/3/2015Downgrade
China Cord Blood Corporation (CO) was downgraded to B- from A- on 8/3/2015 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.0568 to $0.0192, net income declined 38.6% from $4.42M to $2.71M, and EBIT declined 14.8% from $9.32M to $7.94M.
China Cord Blood Corporation (CO) was downgraded to B- from A- on 8/3/2015 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.0568 to $0.0192, net income declined 38.6% from $4.42M to $2.71M, and EBIT declined 14.8% from $9.32M to $7.94M.
A
Buy
4/10/2015Upgraded
China Cord Blood Corporation (CO) was upgraded to A- from B+ on 4/10/2015 due to a noticeable increase in the total return index and volatility index.
China Cord Blood Corporation (CO) was upgraded to A- from B+ on 4/10/2015 due to a noticeable increase in the total return index and volatility index.
B
Buy
3/2/2015Upgraded
China Cord Blood Corporation (CO) was upgraded to B+ from B on 3/2/2015 due to a substantial increase in the growth index, valuation index and efficiency index. Total capital increased 2.55% from $373.5M to $383.02M, and total revenue increased 0.26% from $24.61M to $24.67M.
China Cord Blood Corporation (CO) was upgraded to B+ from B on 3/2/2015 due to a substantial increase in the growth index, valuation index and efficiency index. Total capital increased 2.55% from $373.5M to $383.02M, and total revenue increased 0.26% from $24.61M to $24.67M.
B
Buy
8/12/2014Downgrade
China Cord Blood Corporation (CO) was downgraded to B from B+ on 8/12/2014 due to a significant decline in the growth index, valuation index and total return index.
China Cord Blood Corporation (CO) was downgraded to B from B+ on 8/12/2014 due to a significant decline in the growth index, valuation index and total return index.
B
Buy
8/4/2014Downgrade
China Cord Blood Corporation (CO) was downgraded to B+ from A- on 8/4/2014 due to a decline in the efficiency index, valuation index and total return index.
China Cord Blood Corporation (CO) was downgraded to B+ from A- on 8/4/2014 due to a decline in the efficiency index, valuation index and total return index.
A
Buy
3/3/2014Upgraded
China Cord Blood Corporation (CO) was upgraded to A- from B+ on 3/3/2014 due to an increase in total return and stability.
China Cord Blood Corporation (CO) was upgraded to A- from B+ on 3/3/2014 due to an increase in total return and stability.
OTC PK
03/06/2025 9:51AM Eastern
Quotes delayed
